Ciuleanu, T <br/><br/>
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2016 
 - 680-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Hepatocellular--drug therapy<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Sorafenib<br/>Treatment Outcome